<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024374</url>
  </required_header>
  <id_info>
    <org_study_id>All-E-M-13244-01/02-10-09</org_study_id>
    <nct_id>NCT01024374</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face</brief_title>
  <acronym>13244/2009</acronym>
  <official_title>Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergisa Pesquisa Dermato-Cosmetica LTDA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergisa Pesquisa Dermato-Cosmetica LTDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical single-blind randomized comparison with the overall objective of evaluating the&#xD;
      clinical efficacy of the products Nutracort lotion and Nutracort cream in the treatment of&#xD;
      seborrheic dermatitis on the face.&#xD;
&#xD;
      Will be held clinical and perceived efficacy assessment and instrumental measurements. Each&#xD;
      product will be applied at half face for 7 consecutive days and all applications will be&#xD;
      monitored in the research site. 60 volunteers will be recruited.&#xD;
&#xD;
      Evaluations will be held at the following times: T0 - before the initial application of the&#xD;
      product; T1 - 24 hours after starting treatment, T2 - 48 hours after starting treatment, T3 -&#xD;
      72 hours after initiation of treatment, T4 - 96 hours after the start treatment, T7 - 7 days&#xD;
      after initiation of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Seborrheic Dermatitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects with seborrheic dermatitis on both sides of the face, both sexes, aged 18&#xD;
        to 60 years, skin types I through IV.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
          -  Subjects with seborrheic dermatitis on both sides of the face&#xD;
&#xD;
          -  both sexes&#xD;
&#xD;
          -  aged 18 to 60 years&#xD;
&#xD;
          -  skin types I through IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy / lactation&#xD;
&#xD;
          -  skin condition in the area of application of the product&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  immune insufficiency&#xD;
&#xD;
          -  subjects that are using systemic corticoids&#xD;
&#xD;
          -  subjects that are using immunosuppressors&#xD;
&#xD;
          -  skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis&#xD;
&#xD;
          -  history of reaction to the product category&#xD;
&#xD;
          -  other diseases or medications that might interfere directly in the study or endanger&#xD;
             the health of the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Douglas - P&amp;D</name_title>
    <organization>Galderma</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Seborrheic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

